[ad_1]
Pune-based biotech firm Enzene Biosciences has announced the launch of Bevacizumab, a biosimilar alternative to the more expensive Avastin that is used for treatment of metastatic colorectal cancer.
Bevacizumab is the sixth biosimilar from Enzene Biosciences’s pipeline. “Aimed at penetrating the Indian market for Bevacizumab that is valued at Rs 260 crore, Enzene’s version is the first to be manufactured using the firm’s patented continuous manufacturing process at its Pune facility,” said Dr. Himanshu Gadgil, CEO of Enzene Biosciences Ltd.
“We are confident that the significant price reductions passed on by our partners will greatly benefit thousands of metastatic colorectal cancer patients, supporting our mission to make cancer treatment more accessible and affordable,” he added.
[ad_2]
